News & Updates

A real-world assessment of tirzepatide in Indian clinical practice has shown significant glycaemic and weight benefits in adults with type 2 diabetes (T2D). The medication is also well tolerated, with manageable gastrointestinal side effects, and highly accepted by patients.

A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.

The use of antitumour necrosis factor (anti-TNF) agents for at least 60 months is not only safe but also effective in the treatment of moderate to severe inflammatory bowel disease (IBD), according to a study presented at AIBD 2025.

The addition of low-dose aspirin to warfarin appears to increase the risk of major bleeding in patients with antiphospholipid syndrome (APS) but falls short in reducing all-cause mortality, according to a study presented at ASH 2025. Likewise, the rates of ischemic stroke and acute myocardial infarction are also higher among aspirin users.

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).